Lv51
936 积分 2023-09-20 加入
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
6分钟前
待确认
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
1天前
已完结
Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish–Swedish Population-Based Study
2天前
已完结
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP
2天前
已完结
Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP
3天前
已完结
Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP
3天前
已完结
Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome
3天前
已完结
Revised International Prognostic Index and genetic alterations are associated with early failure to R‐CHOP in patients with diffuse large B‐cell lymphoma
3天前
已完结
Neurological toxicities associated with chimeric antigen receptor T-cell therapy
8天前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
8天前
已完结
皖公网安备34019202002308
